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INTRODUCTION
Endovascular coiling is a standard therapy for intracranial 
aneurysm. Although it has been well documented that 
coiling is superior to clipping, one major drawback of 
coiling is a higher recurrence rate, especially in wide-
neck and/or large aneurysms (1, 2). A flow diverter was 
developed to overcome this drawback. The concept of 
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Objective: We report the results of a pilot clinical study that evaluated the safety and efficacy of a newly-developed, 
retrievable flow diverter (FloWise; Taewoong Medical) for the treatment of internal carotid artery (ICA) aneurysm.
Materials and Methods: A total of 10 patients were enrolled. Inclusion criteria were 1) unruptured aneurysm with a dome size 
of ≥ 8 mm and a neck size of ≥ 4 mm at the ICA, or 2) two or more unruptured aneurysms of any size able to be spanned by a 
single FloWise at the ICA. Co-primary effectiveness end points were technical success of FloWise placement, and a 50% or greater 
decrease in aneurysm volume at the 6-month follow-up angiogram. The primary safety end point was the new development 
of neurological deficits persisting for more than 1-month post-treatment.
Results: Ten patients harboring 14 ICA aneurysms (median diameter, 9.4 mm; range, 2.3–31.0 mm) were enrolled between 
January 2016 and July 2017. FloWise placement was successful in all patients. There were no newly-developed neurological 
deficits during the 6-month clinical follow-up period. One patient did not receive follow-up imaging due to pregnancy. Nine 
patients with 12 aneurysms received a 6-month angiographic follow-up. Ten aneurysms (83.3%) showed decreases in volume 
greater than 50% (mean volume decrease, 82.8 ± 32.9%), of which 8 (66.7%, 95% confidence interval, 35.4–98.0%) showed 
complete occlusion. One patient was retreated due to mass symptom aggravation. 
Conclusions: In this pilot study, FloWise appeared to be safe and effective for ICA aneurysm treatment. A prospective multicenter 
study to validate the effectiveness and safety of FloWise would be worthwhile.
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flow diversion therapy is that when a high metal density 
(low porosity) stent is placed across the aneurysm neck, 
it induces 1) a change in the direction of blood flow away 
from the target aneurysm sac toward the distal parent 
artery, and stasis of blood in the sac resulting in intra-
aneurysmal thrombosis, and 2) an acceleration of the 
neointima formation along the dense stent struts across 
the aneurysm neck. The combination of these effects can 
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result in the exclusion of the aneurysm from circulation, 
and ultimately, aneurysm shrinkage. Since the introduction 
of flow diverters, a growing body of evidence has shown 
that they are more durable, and as a result, there has been 
a rapid increase in their use to treat aneurysms (3-6). 
 Recently, we reported that a newly-developed flow 
diverter (FloWise; Taewoong Medical, Seoul, Korea) was 
effective for aneurysm occlusion when evaluated in an 
elastase-induced rabbit aneurysm model (Fig. 1) (7). Here, 
we report the results of a single-center, prospective pilot 
study with a small number of human subjects. The aim 
of this pilot clinical study was to evaluate the safety and 
efficacy of the FloWise flow diverter. 
MATERIALS AND METHODS
This study was approved by the Institutional Review 
Board, and written informed consent was obtained from 
every patient before enrollment in the study. Verbal 
explanations were given to both the patient, and at least 
one first-degree relative twice, and written informed 
consent was obtained by the primary investigator.
This study was conducted as a single-center, pilot clinical 
study to evaluate the safety and efficacy of FloWise in 
a small population (n = 10) prior to launching a large, 
multicenter prospective study. Inclusion criteria were as 
follows: 1) 18–75 years of age, 2) pre-treatment modified 
Rankin scale score (mRS) of 0–2, 3) unruptured internal 
carotid artery (ICA) aneurysm with a dome diameter ≥ 8 
mm and a neck diameter ≥ 4 mm, or 2 or more unruptured 
ICA aneurysms able to be spanned by a single FloWise, and 
4) written informed consent. Exclusion criteria were as 
follows: 1) currently pregnant, 2) intracranial hemorrhage 
within the last 30 days, 3) untreated aneurysm that had 
ruptured within the last 30 days, 4) any contraindication 
for antiplatelet medication use, 5) major surgery within 
30 days of the treatment, 6) a platelet count of less than 
100000, 7) untreated cancer or immunocompromising 
disease, 8) serum creatinine levels of more than 2.5 mg/dL, 
9) a previously inserted stent in the parent artery harboring 
the target aneurysm, 10) nitinol allergy, 11) uncontrolled 
hypersensitivity to iodine contrast material, 12) active 
infection, and 13) a life expectancy of less than 5 years. 
Ten patients (all women; median age, 56 years; age range, 
28–72 years) harboring 14 ICA aneurysms (median size, 9.4 
mm; range, 2.3–31.0 mm; median neck diameter, 7.1 mm; 
neck diameter range, 2.0–10.2 mm) were enrolled between 
January 2016 and July 2017.
Antiplatelet Medication
All enrolled patients received dual antiplatelet medication 
(100 mg aspirin with 75 mg clopidogrel) for at least 5 
days before treatment. An antiplatelet drug resistance test 
was obtained 1 day before treatment. If the antiplatelet 
resistance test was positive, an antiplatelet drug with a 
different mechanism of action was added. After completion 
of the treatment, dual antiplatelet medication was 
continued for 6 months, and then replaced by aspirin 
monotherapy. 
The Flowise Flow Diverter 
The specifications of the FloWise stent and the in vivo 
experimental results in a rabbit aneurysm model have been 
previously reported (7). Briefly, the FloWise flow diverter 
stent is composed of a braiding of 48 strands of 0.0012-inch 
nitinol and platinum wires. These 48 strands are braided 
and heat-treated in the expanded configuration. After 
deployment from the delivery system, the FloWise expands 
to cover the neck of the aneurysm, forming a high-coverage 
mesh of approximately 33–41% by area, with a radio-
opacity similar to that of the Pipeline Flex (Medtronic, CA, 
USA) embolization device (Fig. 1A). The FloWise is attached 
to a flexible delivery wire, which has radio-opaque end 
markers, and is packaged in an introducer sheath. The distal 
tip of the delivery wire is pre-shaped to a J shape (Fig. 1B). 
The stent-contact portion of the delivery wire is coated 
with silicon so that it grips the FloWise, which allows for 
re-sheathing at any point prior to 70% deployment (Fig. 
1C). This packaged device can be loaded into standard 
microcatheters with at least a 0.027-inch inner diameter. 
It is pushed through the microcatheter and deployed by 
a combination of microcatheter withdrawal and forward 
pressure on the delivery wire. The FloWise undergoes 
approximately 38% shortening when deployed completely. 
The FloWise is available in 3.0, 3.5, 4.0, 4.5, and 5.0 mm in 
diameter, and 20, 25, 30, 35, and 40 mm in length.
Implantation of the Flowise Flow Diverter 
All patients were treated under general anesthesia. 
After placement of a 6-Fr shuttle guide sheath (Shuttle, 
Cook, CA, USA) in the relevant ICA, a 5-Fr intermediate 
catheter (Sofia; Microvention-Terumo, Tustin, CA, USA) was 
advanced through the shuttle sheath up the petrous or 
cavernous segment of the ICA as far as possible. A 0.027-
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inch microcatheter was navigated up to the ipsilateral 
middle cerebral artery M2 or M3 segment using a 0.014-
inch microwire. Then, a FloWise stent that matched the 
largest diameter of the parent artery was introduced into 
the microcatheter and deployed, completely spanning the 
aneurysm neck. After deployment of the FloWise, follow-
up angiograms were obtained at least two times each for 
10 minutes. If enough flow diversion (shift of inflow zone 
from aneurysm distal neck to proximal neck and disruption 
of inflow jet), as judged by an experienced operator, was 
not seen after the first FloWise had been successfully 
implanted, an additional FloWise was inserted in an 
overlapping manner. If an acute in-stent thrombosis was 
detected, glycoprotein IIb/IIIa inhibitor (tirofiban, 0.5–1.0 
mg) was intra-arterially administered and maintained for 12 
hours after completion of the procedure. 
Clinical and Imaging Follow Up 
Outpatient based clinical follow-up was scheduled at one 
and three months post procedure. A computed tomography 
(CT) angiogram was obtained at the 3-month follow-up. The 
patient was then scheduled for readmission at 6 months ± 2 
weeks for follow-up angiography. A data safety monitoring 
board (DSMB) was organized in order to maintain patient 
safety. The DSMB was independently composed of two 
physicians who were not working in the study hospital. 
During the clinical follow-up, telephone and e-mail contact 
with a clinical research assistant was possible at any time. 
If the patient complained of any symptom potentially 
related to the treatment, it was reported to the primary 
investigator as soon as possible. Complaints were recorded 
and the DSMB evaluated whether or not they were related to 
the treatment. Retreatment was planned in the event that, 
at the 6-month follow-up angiogram, the target aneurysm 
was found to be enlarged, causing any new neurological 
symptoms. 
Primary and Secondary Endpoints
Co-primary endpoints included the rate of technical 
success, and a 50% or greater decrease in aneurysm sac 
volume at the 6-month follow-up angiogram. Technical 
success was defined as whether FloWise completely covered 
the neck of the target aneurysm. The secondary endpoint 
was the rate of complete occlusion at the 6-month follow-
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Fig. 1. FloWise (Taewoong Medical) flow diverter.
A. Spot image of FloWise and Pipeline Flex (Medtronic) flow diverters. B. Image of partially deployed FloWise stent. Note distal tip of stent-
loading delivery wire is pre-shaped in J configuration. C. Schematic drawing of FloWise design.
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up angiogram. 
The primary safety endpoint was the development of a 
new neurological morbidity (defined by an mRS score ≥ 
3) that persisted for more than 1 month post-treatment. 
Secondary safety endpoints were the development of new 
symptomatic ipsilateral ischemic stroke ≥ 5 on the National 
Institute of Health Stroke Scale, and an in-stent stenosis of 
more than 50% at the 6-month follow-up angiogram. 
Statistical Analysis
Statistical analysis was performed using IBM SPSS version 
20 (IBM Corp., Armonk, NY, USA). Continuous variables are 
presented as the mean ± standard deviation, and categorical 
variables as numbers and percentages. The rates of primary 
and secondary end points were assessed at 6 months and 
presented as numbers and percentages. 
RESULTS
FloWise placement was successful in all 10 patients. 
Eight patients were treated with a single FloWise stent, 
one patient was treated with two, and one patient was 
treated with three overlapping FloWise stents in order to 
obtain more flow diversion. Table 1 summarizes patient and 
aneurysm characteristics and 6-month follow-up results. 
No new neurological deficits developed during the 
6-month clinical follow-up period. Nine patients with 
12 aneurysms received 6 months of angiographic follow-
up. One patient did not receive follow-up imaging due to 
pregnancy. One patient was retreated with Pipeline Flex due 
to lack of change in aneurysm volume, and progressive mass 
symptom aggravation. The patient’s symptoms resolved 
completely after 1 month of retreatment and resulted 
in complete occlusion of the aneurysm 6 months post-
treatment. Ten aneurysms (83.3%) showed a 50% or more 
decrease in volume (mean volume decrease, 82.8 ± 32.9%) 
of which 8 (66.7%, 95% confidence interval, 35.4–98.0%) 
showed complete occlusion (Fig. 2). One patient, who had 
three overlapping FloWise stents, showed asymptomatic in-
stent stenosis ≥ 50% (Fig. 3). At 12 months, 10 aneurysms 
(83.3%) showed complete occlusion.
DISCUSSION
In this pilot prospective clinical study, FloWise showed 1) 
no treatment-related complications, 2) an aneurysm volume 
decrease of 50% or more in 83.3% of the treated aneurysms 
at 6 months, and 3) complete occlusion of 66.7%, and 
83.3% of target aneurysms at 6 months and 12 months, 
respectively. 
Endovascular treatment is one of the standard treatments 
for intracranial aneurysms and has been shown to be 
superior to clipping in the majority of reports (1, 2, 8). 
However, conventional endovascular coil embolization 
yields low complete occlusion rates and high recurrence 
rates, especially in wide-necked, large, and giant aneurysms 
Table 1. Patients and Aneurysm Characteristics, and 6-Month Follow-Up Results
Pt Sex/Age Location
Dome Size 
(mm)
Neck Size 
(mm)
Aneurysm Occlusion  
at 6 Months
Volume Decrease  
at  6 Months (%)
mRS Comments
1 F/56 Left ICA paraclinoid 8.3 5.5 Complete 100 0
2 F/52 Left ICA paraclinoid 17.8 8.9 No change 0 0
Retreatment (Pipeline 
Flex*) at 6 months
3 F/42 Right ICA paraclinoid 11.0 8.15 Neck remnant 85 0
4 F/62 Right ICA paraclinoid 9.4 8.83 Complete 100 0
5 F/59 Left ICA paraclinoid 8.2 8.4 Incomplete 33 0
6 F/28
Right ICA ophthalmic 4.5 4.2 NA NA 0 Lost to imaging follow-
up due to pregnancyRight ICA paraclinoid 4.0 4.0 NA NA 0
7 F/72
Left ICA paraclinoid 11.0 6.7 Neck remnant 100 0
Left ICA ophthalmic 2.3 2.0 Complete 100 0
8 F/52 Right ICA paraclinoid 15.4 5.5 Complete 100 0
9 F/57
Right ICA paraclinoid 15.3 10.6 Partial occlusion 73 0
Right ICA paraclinoid 31.0 7.5 Complete 100 0
10 F/67
Left ICA paraclinoid 2.5 2.0 Complete 100 0
Left ICA paraclinoid 2.0 2.0 Complete 100 0
*Pipeline Flex, Medtronic. F = female, ICA = internal carotid artery, mRS = modified Rankin scale score, NA = not applicable, Pt = number 
of patient 
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(8-10). With advanced techniques, such as a multi-catheter, 
balloon, stent assistance, or a combination of these 
techniques, most difficult aneurysms can be treated (11-
16). However, advanced techniques require more technical 
demands, and, as a result, a number of complex or fusiform 
aneurysms remain uncoilable (3). A treatment with multiple 
overlapping stents was initially developed for flow diversion 
therapy in dissecting, blister-like, or fusiform aneurysms 
and had shown promising results (17-25). In addition, 
in vitro experimental studies showed a high probability 
of success when implementing flow diversion therapy for 
aneurysm treatment (26, 27). Based on the results of 
clinical and experimental studies, flow diverter stents have 
been developed for the treatment of wide-necked, large, 
and giant aneurysms, which are difficult to treat with 
coiling (3, 28). A growing body of evidence is available on 
the effectiveness of flow diverters for treating various types 
of aneurysms (3-6). There have been several commercially 
available flow diverters; Pipeline Flex, SILK (Balt Extrusion, 
Montmorency, France), Surpass Streamline (Stryker 
Neurovascular, Fremont, CA, USA), FRED (Microvention-
Terumo). The characteristics of these flow diverters are 
summarized in Table 2. 
Until recently, there were several flow diverter types 
commercially available in Korea, and a multicenter 
experience was reported (29). However, these flow diverters 
were quite expensive and required technical expertise. As 
a result, aneurysm treatment with commercially available 
A B C
D E F
Fig. 2. 52-year-old woman presented with large aneurysm at right ICA paraclinoid segment. 
A. Right carotid angiogram shows 15.4-mm-sized aneurysm at ICA paraclinoid segment. B. Spot image during FloWise deployment. Note that 
distal tip of FloWise loading delivery wire is pre-shaped in J configuration (arrow). C. Spot image 10 minutes after FloWise deployment shows 
that contrast materials still remain in aneurysm sac. D. 6-month follow-up angiogram shows complete occlusion of aneurysm. E. Initial T2-
weighted MR image shows large aneurysm (arrow) at intradural portion of right ICA. F. 12-month follow-up T2-weighted MR image shows 
disappearance of aneurysm. ICA = internal carotid artery, MR = magnetic resonance
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Fig. 3. 57-year-old woman presenting with recurrent aneurysms 10 years after wrapping of giant aneurysm at right ICA paraclinoid 
segment.
A. Initial right carotid angiogram shows giant aneurysm. B. Right carotid angiogram 10 years after initial treatment shows large aneurysm at 
supraclinoid segment and partially thrombosed giant aneurysm at paraclinoid segment. C. Right carotid angiogram just after three FloWise 
stent placements. D. Aneurysm flow before (left) and after (right) shows marked flow diversion effect. Note inflow zone is shifted from distal 
to proximal neck and inflow jets do not reach aneurysm dome. Arrows in the sac and their magnitude indicate flow direction and velocity, 
respectively. E. Flat-panel computed tomography image immediately after treatment with three overlapping FloWise stents. Arrowheads indicate 
outline of partially thrombosed giant aneurysm at paraclinoid segment of right ICA. F. 6-month follow-up angiogram after treatment with three 
FloWise stents shows complete occlusion of giant aneurysm at paraclinoid segment and decrease in size of large aneurysm at supraclinoid 
segment. Degree of stenosis between two aneurysms was aggravated, but patient remained asymptomatic. G. 12-month follow-up angiogram 
shows greater decrease in size of aneurysm at supraclinoid segment and slight improvement of stenosis.
A B C
D E F
G
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flow diverters is very limited in Korea and has resulted in 
considerable one-month mortality rates (30). 
We developed a new flow diverter that is easy to use 
and resheathable. It has a metal density of approximately 
33–41%, depending on the relationship between the 
parent vessel and stent diameter, which is comparable 
to other commercially available flow diverters (31). This 
pilot study was conducted to preliminarily evaluate the 
safety and effectiveness of the FloWise flow diverter 
before a prospective multicenter study. FloWise placement 
was successful in all patients, and there were no newly-
developed neurological symptoms during the 6-month 
follow-up period. However, it has been reported in the 
literature that other commercially available flow diverters 
have shown combined major morbidity and neurological 
mortality rates of 5.6–7.7% (4, 5). Due to the small 
sample size of this pilot study, it cannot be assumed that 
the FloWise flow diverter is safer than other commercially 
available flow diverters. One explanation for the absence of 
complication in this pilot study is that all procedures were 
done by a single operator who had extensive experience 
in commercially available flow diverters. Given that 
implantation of a flow diverter stent requires considerable 
technical expertise, placement by an experienced operator 
might be helpful to avoid periprocedural complications. 
Additionally, in cases that an operator judged flow diversion 
to be insufficient after implantation of the first FloWise, 
additional devices were overlapped until flow diversion 
appeared to be sufficient. In the authors’ opinion, this 
may help to avoid delayed complications, such as aneurysm 
rupture. Complete occlusion was observed in 66.7% and 
83.3% of target aneurysms at 6 months and 12 months, 
respectively, after FloWise implantation. These rates are 
comparable with the rates reported in the literature (55.7–
93.3%) (32). Although the sample size was small, the safety 
and effectiveness of FloWise did not appear to be inferior to 
the safety and effectiveness of commercially available flow 
diverters. If FloWise’s safety and effectiveness is validated 
in a larger population, FloWise could be an additional tool 
for flow diversion therapy in intracranial aneurysms.
In conclusion, FloWise appears to be a safe and effective 
treatment for unruptured ICA aneurysms. A prospective 
multicenter study to validate the safety and effectiveness of 
the FloWise stent would be worthwhile. 
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